|
07 Jan 2026 |
Sharda Cropchem
|
Consensus Share Price Target
|
830.40 |
1165.40 |
- |
40.34 |
buy
|
|
|
|
|
05 Dec 2025
|
Sharda Cropchem
|
FundsIndia
|
830.40
|
1045.00
|
868.25
(-4.36%)
|
25.84 |
Buy
|
|
|
Edge: High-entry-barrier regulatory portfolio + scalable global network
|
|
04 Nov 2025
|
Sharda Cropchem
|
Khambatta Securities
|
830.40
|
1184.00
|
816.80
(1.67%)
|
42.58 |
Buy
|
|
|
SCL reported a robust performance in 2Q FY26, driven by strong volume growth and margin expansion. The Company remains optimistic about a gradual recovery in the global agrochemical market, noting that inventories have normalized across distribution channels.
|
|
01 Nov 2025
|
Sharda Cropchem
|
Anand Rathi
|
830.40
|
1250.00
|
864.70
(-3.97%)
|
50.53 |
Buy
|
|
|
Healthy, 35% y/y, volume growth and market-share gains in its key regions drove Sharda Cropchem’s Q2 results. Growth improved on better demand particularly in NAFTA and Europe coupled with near complete de-stocking across major regions.
|
|
21 Aug 2025
|
Sharda Cropchem
|
Khambatta Securities
|
830.40
|
1162.00
|
951.80
(-12.75%)
|
39.93 |
Buy
|
|
|
Sharda Cropchem Limited (SCL) reported a 25% y-o-y increase in total revenue for 1Q FY26, reaching Rs 984.8 crore.
|
|
28 Jul 2025
|
Sharda Cropchem
|
Anand Rathi
|
830.40
|
1250.00
|
1090.45
(-23.85%)
|
50.53 |
Buy
|
|
|
Healthy, 13% y/y, volume growth and market-share gains in its key regions drove Sharda Cropchem’s Q1 results. Growth improved on the back of better demand scenario particularly in Europe and a near complete destocking across major regions.
|
|
03 Jun 2025
|
Sharda Cropchem
|
Khambatta Securities
|
830.40
|
793.00
|
764.90
(8.56%)
|
Target met |
Hold
|
|
|
Sharda Cropchem Limited (SCL) reported solid growth in 4Q FY25 as revenues increased by 39.4% y-o-y to Rs 1,828.5 crore. This robust quarterly growth was mirrored by a strong overall top-line performance for the entirety of FY25.
|
|
05 Mar 2025
|
Sharda Cropchem
|
Anand Rathi
|
830.40
|
730.00
|
540.00
(53.78%)
|
Target met |
Buy
|
|
|
We recently met Sharda Cropchem’s Chairman and MD, Mr R V Bubna to gauge the business outlook. Management is confident of achieving double-digit revenue growth (guidance raised 26% y/y post Q3 results vs. 15-20% earlier) in FY25, particularly due to volumes and penetration into new markets.
|
|
27 Jan 2025
|
Sharda Cropchem
|
Anand Rathi
|
830.40
|
730.00
|
569.10
(45.91%)
|
Target met |
Buy
|
|
|
A gradual price increase, volume growth across regions and a good product mix drove Sharda Cropchem’s better-than-expected Q3 results. Growth would improve ahead as de-stocking is now complete
|
|
27 Jan 2025
|
Sharda Cropchem
|
Khambatta Securities
|
830.40
|
770.00
|
569.10
(45.91%)
|
Target met |
Buy
|
|
|
? Sharda Cropchem Limited (SCL) reported solid growth in 3Q FY25 as revenues increased by 46.9% y-o-y to Rs 929.3 crore, fuelled by a robust increase in sales volume and a strategic price adjustment. Growth was observed across regions, with Europe and North America exhibiting strong performance. ? Gross margin expanded by 650 bps y-o-y to 32.7%.
|
|
29 Oct 2024
|
Sharda Cropchem
|
Khambatta Securities
|
830.40
|
729.00
|
710.25
(16.92%)
|
Target met |
Hold
|
|
|
Sharda Cropchem Limited (SCL) reported solid growth in 2Q FY25 as revenues increased by 33.8% y-o-y to Rs 776.9 crore. A volume growth of 21% y-o-y was driven by strong performance at the agrochemical segment with Europe being the key contributor.
|
|
30 Jul 2024
|
Sharda Cropchem
|
Khambatta Securities
|
830.40
|
676.00
|
557.05
(49.07%)
|
Target met |
Buy
|
|
|
Sharda Cropchem Limited (SCL) reported solid growth in 1Q FY25 as revenues increased by 23.1% y-o-y to Rs 785.1 crore. A volume growth of 41% y-o-y was driven by strong performance at the agrochemical segment.
|
|
25 Oct 2023
|
Sharda Cropchem
|
Prabhudas Lilladhar
|
830.40
|
470.00
|
411.25
(101.92%)
|
Target met |
Accumulate
|
|
|
|
|
24 Jul 2023
|
Sharda Cropchem
|
Prabhudas Lilladhar
|
830.40
|
540.00
|
481.35
(72.51%)
|
|
Accumulate
|
|
|
|
|
25 Jul 2022
|
Sharda Cropchem
|
Prabhudas Lilladhar
|
830.40
|
740.00
|
529.25
(56.90%)
|
|
Buy
|
|
|
|
|
17 May 2022
|
Sharda Cropchem
|
Khambatta Securities
|
830.40
|
836.00
|
699.25
(18.76%)
|
|
Buy
|
|
|
|
|
16 May 2022
|
Sharda Cropchem
|
Anand Rathi
|
830.40
|
835.00
|
707.60
(17.35%)
|
|
Buy
|
|
|
|
|
27 Jan 2022
|
Sharda Cropchem
|
Anand Rathi
|
830.40
|
600.00
|
602.35
(37.86%)
|
Target met |
Buy
|
|
|
|
|
27 Jan 2022
|
Sharda Cropchem
|
Khambatta Securities
|
830.40
|
566.00
|
602.35
(37.86%)
|
Target met |
Buy
|
|
|
|
|
24 Jan 2022
|
Sharda Cropchem
|
Prabhudas Lilladhar
|
830.40
|
570.00
|
525.35
(58.07%)
|
Target met |
Buy
|
|
|
Sharda Cropchem (SHCR) reported strong operational performance in 3QFY22, primarily led by healthy revenue growth across regions. Key highlights are: (1) Volume/Price/FX growth of 51%/26.5%/1% YoY respectively; (2) Gross margin declined 60bps YoY to 33.9% led by higher freight cost; (3) Better operating leverage coupled with superior geographical and product mix has resulted into EBITDA margins expansion of 250bps YoY to 22% (incl. IU&AD write-offs of Rs70mn in 3QFY22); and (4) Working capital days up by 1-day YoY to 72. Citing a positive growth momentum across...
|
|
05 Mar 2021
|
Sharda Cropchem
|
Prabhudas Lilladhar
|
830.40
|
383.00
|
314.00
(164.46%)
|
Target met |
Buy
|
|
|
We maintain reduce rating (TP- Rs 676) on CRIN due to capacity constraints in NPK and likely headwinds on the raw material side starting 4Q. We are positive on Urea companies given healthy volumes and significantly lower...
|